Abstract 2049P
Background
Osimertinib is a third-generation tyrosine kinase inhibitor (TKI) that is the standard of care treatment for non-small cell lung cancer (NSCLC) with EGFR driver mutation. Some of the most common treatment-related adverse events (TRAEs) are rash, diarrhea, nausea, paronychia, and stomatitis. This abstract aims to describe muscle cramps as TRAEs associated with osimertinib use.
Methods
EGFR mutant NSCLC patients using osimertinib were included. Data were collected during pharmaceutical consultations and remote telemonitoring between January 2016 and April 2023. In all consultation modalities, drug interactions, drug reconciliation, adherence to treatment using the Morisky Medication Adherence Scale (MMAS) tool, classification and grading of TRAEs according to Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 were evaluated.
Results
A total of 88 patients were included. Mean age was 68 years and 71% were female. The pharmacist performed medication reconciliation and analysis of drug interactions in all patients and 99% of them showed good adherence to treatment. In the evaluation of TRAEs, 29% reported muscle cramps, with 19% of the sample developing grade 2. The median onset of the event was 2 months after starting osimertinib. Around 57% of the patients had diarrhea, which was managed early after the initial symptoms. Therefore, the occurrence of muscle cramps was not related to hydroelectrolytic unbalance due to diarrhea. The main osimertinib registration studies did not report muscle cramps as TRAEs.
Conclusions
In our cohort muscle cramps were very common TRAEs associated with osimertinib use and have not been directly related to diarrhea. It is an underreported adverse event that can impact on quality of life. Pharmaceutical follow-up is strategic for post-marketing surveillance, playing an important role in identifying new TRAEs. Update on muscle cramps as a very common TRAEs for osimertinib is required to develop supportive measures in conjunction with the multidisciplinary team, support clinical data and add to regulatory agency records.
Clinical trial identification
Research Ethics Committee approval CAAE: 19918319.1.0000.5533.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2096P - Morphine titration with intravenous patient-controlled analgesia for severe cancer pain (Mr.TIPS)
Presenter: Seok Jae Huh
Session: Poster session 06
2097P - Incidence, risk factors (RFs) and management of oral mucositis (OM) in patients (pts) treated with a fluoropyrimidines (FP)-based therapy (tp): A retrospective, monocentric experience
Presenter: Fiorella Manfredi
Session: Poster session 06
2098P - The impact of concomitant use of non-opioid analgesics and immune checkpoint inhibitors on survival in lung cancer patients: A Hong Kong population-based cohort study
Presenter: Zheng-Hao Ye
Session: Poster session 06
2099P - The role of ambulatory blood pressure measurement in TKI-induced arterial hypertension diagnosis
Presenter: Elina Khachaturian
Session: Poster session 06
2100P - An exploratory study of the efficacy and safety of hetrombopag in the treatment of thrombocytopenia induced by concurrent or sequential chemoradiotherapy
Presenter: Jun Wang
Session: Poster session 06
2101P - Bleeding Induced by ANtiCAncer drugs (BIANCA) used breast cancer
Presenter: Nicolas Janus
Session: Poster session 06
2102P - Changes in opioid usage after intrathecal morphine pump implantation in patients with terminal cancer (pilot study)
Presenter: Eun Joo Choi
Session: Poster session 06
2103P - Phase Ib, international, dose-escalation study to evaluate the safety, pharmacokinetics (PK) and efficacy of ST-617 a dithiolethione, for the attenuation of oral mucositis (OM) in patients receiving chemoradiation (CRT) for head & neck (H&N) cancer
Presenter: Daniel Osei-Fofie
Session: Poster session 06
2104P - Prevention of taxane chemotherapy induced nail changes and peripheral neuropathy by application of extremity cooling: A prospective single center study with intrapatient comparison
Presenter: Kristen Johnson
Session: Poster session 06
2105P - Prophylactic role of a postbiotic microbiota-stabilizer on abemaciclib-induced diarrhea in breast cancer patients: A pilot application study
Presenter: Rita De Sanctis
Session: Poster session 06